Wasserundurchlässige Dächer und Decken in Betonbauweise, sogenannte “Weiße Dächer und Decken” oder kurz “WU‐Dächer”, folgen der in über vier Jahrzehnten entwickelten und angewandten WU‐Bauweise. Der Kenntniszuwachs aus Praxis und Grundlagenforschung der WU‐Bauweise ermöglicht mittlerweile die zielsichere Errichtung von Bauwerken, bei denen die konstruktiven Betonbauteile auch die dichtende Funktion gegenüber drückendem und nichtdrückendem Wasser erfolgreich übernehmen. Wie bei den für Bodenfeuchte und drückendes Wasser ausgelegten “Weißen Wannen” gilt die DAfStb‐Richtlinie “Wasserundurchlässige Bauwerke aus Beton” (WU‐Richtlinie) grundsätzlich auch für die WU‐Bauweise von Dächern und Decken. Dieser Beitrag befasst sich mit den planerischen und konstruktiven Besonderheiten dieser Bauweise, die sich ergänzend zu den Regelungen der o.g. Richtlinie bewährt haben und daher bei Planung und Bauausführung Beachtung finden sollten. Neben den mittlerweile bewährten Planungs‐ und Konstruktionsgrundsätzen wird auch der aktuelle Erfahrungsstand aus Sicht von Planern und Bauausführenden dargestellt.Waterproof Concrete Roofs and FloorsWaterproof roofs and floors have been built for more than four decades in the construction of buildings, industrial facilities etc. The rules of the Code of Practice for Waterproof Concrete Structures published by the German Committee for Reinforced Concrete (DAfStb e. V.) also apply to waterproof roofs but they do not include detailed provisions regarding roofs and floors. Beyond the design and construction principles of the code of practice this paper gives additional information about design principles, concrete technology, and construction work that should be considered to ensure the quality of a waterproof reinforced concrete roof.
Pharmacokinetics of ofloxacin in plasma and peritoneal fluid were studied in 11 patients on continuous ambulatory peritoneal dialysis (CAPD). Seven patients without peritonitis received 20 mg ofloxacin added to 2L dialysate i.p. every 6 h for one day only, while 4 patients with acute peritonitis were treated with this same dosage every 4 h for 3 days, then every 6 h for the next 7 days. Ofloxacin concentrations in plasma and dialysate were determined by HPLC. After i.p. drug application there was a rapid elimination of ofloxacin from dialysate, this being significantly faster in patients with peritonitis as compared to those without. Likewise, the total amount lost from the first bag after a 3 h dwell was higher in the peritonitis group (84.7±1.5%; mean±SEM) than in the non-peritonitis group (75.6±2.1 %). Twenty-four h after start of ofloxacin treatment, the mean peritoneal fluid concentrations at the end of each exchange studied were all above 3 mg/L. In patients with peritonitis, plasma concentrations of ofloxacin rose to 0.94±0.05 mg/L after 24 h reaching a Cmax of 1.8±0.2 mg/L after a tmax of 84±23 h.lntraperitoneal administration of ofloxacin was well tolerated, and no local or systemic adverse events were observed. Peritonitis episodes that were caused by Staphylococcus epidermidis (3) and by E. coli (1) were cured in all patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.